Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kokosi (London, United Kingdom), A. Trachalaki (London, United Kingdom), C. Stock (London, United Kingdom), J. Donovan (London, United Kingdom), E. Tsitoura (Herakleion, Greece), V. Kouranos (Londonn, United Kingdom), P. George (Londonn, United Kingdom), P. Molyneaux (Londonn, United Kingdom), F. Chua (Londonn, United Kingdom), T. Maher (Londonn, United Kingdom), E. Renzoni (Londonn, United Kingdom), N. Tzanakis (Herakleion, Greece), A. Wells (London, United Kingdom), K. Antoniou (Herakleion, Greece). Serum KL-6 identifies ILD patients with a progressive fibrosing phenotype. 445

Member's Comments

No comment yet.

Related content which might interest you: Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Serum chitotriosidase levels in granulomatous lung disorders Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006 Elevated serum LOXL2 levels are associated with rapid disease progression in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Serum KL-6 and SP-D as useful clinical indicators of interstitial changes and pulmonary functional abnormality in patients with Sjogren's syndrome Source: Eur Respir J 2001; 18: Suppl. 33, 367s Year: 2001 Serum progranulin levels in idiopathic pulmonary fibrosis and other interstitial lung diseases Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis Source: Annual Congress 2004 - Fibrosing lung diseases Year: 2004 KL-6 serum levels in adult cystic fibrosis patients Source: Annual Congress 2011 - Cystic fibrosis: clinical and laboratory studies Year: 2011 Serum CYFRA reflects disease severity of autoimmune pulmonary alveolar proteinosis Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Plasma fibronectin as the criterion of idiopathic fibrosing alveolitis severity Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 KL-6 compared to LDH as a prognostic factor in Caucasian patients with idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 YKL-40 and KL-6 in serum and sputum samples of patients diagnosed with hypersensitivity pneumonitis. Source: International Congress 2019 – Environment, work and respiratory health in occupational and environmental lung diseases Year: 2019 KL-6 as a potential therapeutic biomarker in fibrosing interstitial lung diseases Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Prognostic role of CCL18 serum concentrations in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007 Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity Source: Eur Respir J 2005; 26: Suppl. 49, 21s Year: 2005 Elevation of serum tumor markers in patients with interstitial lung disease Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011 Serum KL-6 elevation related with severity in patients with pneumocystis pneumonia Source: Annual Congress 2011 - Infection in the immunocompromised host: infrequent aetiologies Year: 2011 MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Diagnostic utility of serum KL-6 levels in acute respiratory failure with bilateral pulmonary infiltrates Source: Virtual Congress 2020 – Experimental and laboratory studies in intensive care unit medicine Year: 2020